Findings from GSK Vaccines Broaden Understanding of Herpes Zoster Vaccine (Safety and Efficacy of Recombinant and Live Herpes Zoster Vaccines for Prevention In At-risk Adults With Chronic Diseases and Immunocompromising Conditions).

Keywords: Mississauga; Canada; North and Central America; Biological Products; Business; Chickenpox Vaccines; Chronic Disease; Communicable Disease Control; DNA Virus Infections; DNA Viruses; Disease Attributes; Environment and Public Health; Genetics; Health and Medicine; Herpes Zoster; Herpes Zoster Vaccine; Herpes Zoster Virus; Herpesviridae Infections; Herpesvirus; Herpesvirus Diseases and Conditions; Herpesvirus Vaccines; Immunization; Immunization and Public Health; Pharmaceutical Companies; Public Health; Public Health Practice; Risk and Prevention; Vaccination; Vaccines; Varicella Vaccines; Viral Vaccines; Virology; Zoster Vaccine EN Mississauga Canada North and Central America Biological Products Business Chickenpox Vaccines Chronic Disease Communicable Disease Control DNA Virus Infections DNA Viruses Disease Attributes Environment and Public Health Genetics Health and Medicine Herpes Zoster Herpes Zoster Vaccine Herpes Zoster Virus Herpesviridae Infections Herpesvirus Herpesvirus Diseases and Conditions Herpesvirus Vaccines Immunization Immunization and Public Health Pharmaceutical Companies Public Health Public Health Practice Risk and Prevention Vaccination Vaccines Varicella Vaccines Viral Vaccines Virology Zoster Vaccine 2023 FEB 24 (NewsRx) -- By a News Reporter-Staff News Editor at Vaccine Weekly -- New research on Immunization and Public Health - Herpes Zoster Vaccine is the subject of a report. Clinicians should consider HZ vaccination in eligible at-risk populations to protect against HZ and its associated complications and thereby, reduce the burden that HZ poses on the healthcare system. [Extracted from the article]